The August 2026 approval of Tauklarify gives families facing younger-onset Alzheimer's a new brain-scan option during workups. The scan detects tau tangles, twisted tau protein clumps that track memory decline. For adults under 65 with unclear symptoms, it can sharpen diagnosis and staging.
It does not replace the clinic visit, memory testing, or amyloid checks. It adds a tau-specific result doctors can use in select cases. Families can now ask whether that result would change care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the new tau scan does
- Why age under 65 changes the decision
- Where blood tests fit now
- What to ask at the memory clinic
What the new tau scan does
Tauklarify is florquinitau F 18, formerly called MK-6240. Lantheus states in the FDA approval notice that FDA approved it Aug. 14, 2026 for brain PET in cognitively impaired adults evaluated for Alzheimer's. Its purpose is to identify tau tangle pathology. The approval rested on two studies with five blinded readers per study.
NeurologyLive reports in its approval report that positive agreement ranged 68%-88% and negative agreement ranged 93%-99%. Inter-reader agreement was strong, supporting a tau-positive versus tau-negative read. In practice, that means a clear negative scan weighs against heavy tau spread. A clear positive scan points toward Alzheimer's-type tau. Borderline or early-stage cases remain harder to read.
Why age under 65 changes the decision
Symptoms before 65 often look atypical. Work problems, language loss, visual trouble, or mood shifts may come first. Other causes need ruling out, and the stakes for work and family are high. Joint Alzheimer's Association-SNMMI criteria rate tau PET appropriate in five situations.
Applied Radiology summarizes in its criteria summary that those include MCI or dementia under 65 with suspected Alzheimer's and cases with atypical features. That language directly covers younger-onset workups. The same criteria separate amyloid and tau roles. Amyloid PET is more sensitive for early pathology, while tau burden tracks clinical progression. Tau PET therefore complements amyloid testing for staging and prognosis rather than duplicating it.
Where blood tests fit now
Many families can start with blood work before PET. The Alzheimer's Association guidance says only blood tests with at least 90% sensitivity and 90% specificity may substitute for PET or spinal-fluid confirmation. It warns many commercial tests fall short and are not interchangeable. For younger adults, access expanded in 2026.
Reporting on FDA clearance says C2N's PrecivityAD2 is cleared for symptomatic adults as young as 40. It uses amyloid and tau peptide ratios to assess amyloid pathology alongside clinical evaluation, not alone. That sequence matters for cost and burden. A validated blood result plus exam may settle the question. Tau PET then stays for unclear results, atypical syndromes, or staging questions.
What to ask at the memory clinic
Label limits still apply. Practical Neurology's summary of the FDA label notes safety and effectiveness are not established for non-Alzheimer tauopathies. Performance may be lower at earlier stages, a negative scan does not exclude tangles, and a positive scan does not equal histopathologic proof.
Availability also varies. Lantheus says broader commercial availability is still being assessed. Families should expect uneven access by center and insurer in early months. Bring a one-page timeline with dates, examples, medications, sleep, mood, and head injury history to that visit.
- Bring onset age, first symptoms, work impact, and family history
- Ask whether a validated blood biomarker comes first
- Ask whether amyloid status is already known
- Ask how a tau-positive or tau-negative result would change diagnosis, treatment, trial options, or counseling
- Ask about radiation, cost, prior authorization, and scan-site experience
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
